Cytokine expression at the maternal-fetal interface is well documcnted (1). Developmental changes in levels of TNF-a, IL-1P, and IL-6 have been described in both placental tissue and amniotic fluid (2) , with significant rises in all three occurring at the time of labor. However, the precise role of any of these cytokines in either maintaining normal pregnancy or initiating labor remains unknown. Wegmann and coworkers have suggested a critical role for cytokines in normal pregnancy, both for the maintenance of placental growth (3) and the modulation of maternal immune responses to prevent "rejection" of the semiallogenie conceptus (4) . A central feature of Wegmann's hypothesis is that the cytokine interactions that characterize the maternal-fetal relationship are bidirectional and that both maternal and fetal (or fetally derived) tissucs and cclls participate in mutual regulatory responses (5) .
The precise role of the fetus in the putative cytokine regulatory nctwork of pregnancy has not been investigated. Abbas et 01. (6) have demonstrated the presence of TNF-a in fetuses as early as 12 wk of gestation. TNF-a levels were higher in fetuses of greater gestational age, suggesting that fetal levels of this cytokine parallel those in amniotic fluid. However, almaternal and fetal blood as early as the 21st wk of gestation. These results support a potential role for the fetus in the bidirectional cytokine signaling of pregnancy. (Pediatr Res 37: 450-454, 1995) Abbreviations PCR, polymerase chain reaction rtPCR, reverse transcriptase polymerase chain reaction TNFa, tumor necrosis factor-a though these authors concluded that the TNF-a detected in fetal plasma was of fetal origin and coincided with the devclopment of the fetal monocyte-macrophage system, the precise origin of the fetal plasma TNF-a could not be determined. It is equally possible that the TNF-a detected in fetal plasma was derived from placental or decidual cells, which communicate directly with the fetal circulation.
PCR techniques provide a convenient means of addressing issues related to the fetal cytokine repertoire. Although the presence of a specific cytokine in fetal plasma may not be conclusive evidence that the fetal immune system does secrete or is capable of secreting that cytokine (inasmuch as cytokines may pass from placental tissue to the fetus), the presence of cytokine mRNA in fetal blood cells would support the hypothesis that cytokine expression occurs in the fetus as well as in placental tissue. The small amounts of RNA availablc in fetal blood specimens obtained by cordocentesis may yield considerable information about fetal cytokine mRNA transcripts and therefore the role of the fetus itself in the bidirectional cytokine signaling proposed by Wegmann et al. (5) . We used rtPCR to examine maternal and fetal mRNA transcripts in the late second and third trimesters. 
METHODS
Patients and patient specimens. Specimens from 16 pregnancies were studied. In two cases, blood from the mother and from each fetus of a twin pregnancy was available for study (therefore, 16 mothers and 18 fetuses were studied). Blood was obtained by cordocentesis from fetuses at 21 to 39 wk of gestation after prior written informed consent was obtained from the mothers. The procedure for cordocentesis has previously been described (7) . Gestational ages of fetuses and indications for cordocentesis are given in Table 1 . Samples were drawn into sterile EDTA tubes and carried to the laboratory. Plasma was separated from cells by centrifugation, and cell pellets were stored at -70°C until used.
Isolation of RNA from whole blood. RNA was isolated from whole blood by a method modified from that described by Chomczynski and Sacchi (8) . Two hundred p L of whole blood were placed in 500 p L of denaturing solution consisting of 4.0 M guanidinium thiocyanate, 25 mM sodium citrate, 0.5% sodium N-laurosarcosine, and 0.1 M 2-mercaptoethanol, with 20 p g polyinosinic acid used as carrier RNA. Samples were vortexed and 200 p L of 95% ethanol added. Samples were then placed on ice for 5 rnin and subjected to centrifugation in a microfuge at 10 000 X g for 15 rnin at 4°C. Supernates were discarded and pellets dissolved in 150 p L of denaturing solution and 15 p L of 2.0 M sodium acetate, pH 4.2. Solubilized pellets were then incubated on ice for 10 rnin with an equal volume of phenol-chloroform solution (10:4 vol/vol) and subjected to centrifugation at 10 000 X g for 15 min at 4°C. The aqueous phase was saved and precipitated with an equal volume of isopropyl alcohol, with samples incubating at -20°C for 30 min. After incubation, samples were centrifuged at 10 000 X g for 15 min at 4OC and supernatants discarded. Pelleted RNA was washed once with 75% ethanol and dissolved in sterile water with 0.1% diethylprocarbinate. RNA was either frozen at -20°C or used immediately for reverse transcription reactions.
Reverse transcription of RNA to DNA. Reverse transcription of RNA to DNA was accomplished with Moloney murine leukemia virus reverse transcriptase and random hexamer primers using commercially available reagents (GeneAmp, Perkin Elmer Cetus, Norwalk, CT). Conditions for reverse transcription were 50 mM KCl, 10 mM Tris-HC1 (pH 8.3), 5.0 PCR and agarose gel electrophoresis to detect cytokine mRNA. Oligonucleotide primers for TNF-a, IL-1P, and P-actin were obtained from a commercial source (Clontech, Palo Alto, CA). Sequences of the 5' and 3' primers for each cytokine are given in Table 2 .
and 4°C cycles. Samples were then solubilized in 6X buffer consisting of 0.25% bromphenol blue, 0.25% xylene cyanol, and 30% glycerol and subjected to electrophoresis in 1.8% agarose-ethidium bromide gels. Gels were examined for bands of appropriate molecular weight and compared with a positive control generated from a cDNA fragment provided with the primer sets encompassing the sequences amplified in the PCR process. p-actin was also used as a positive control and to determine the efficiency of RNA isolation and cDNA amplification.
Southern blot analysis of amplified PCR products. In selected cases, verification of the identity of the PCR product was performed using Southern blot analysis using commercially available cDNA probes for the sequences amplified in the PCR reactions (Clontech, Palo Alto, CA). Probes were labeled with horseradish peroxidase using commercially available reagents (ECL chemiluminescence detection system, Amersham, Arlington Heights, IL). PCR products were transferred to nylon membranes by capillary action overnight in 1.5 M NaCl and 0.5 M NaOH. Prehybridization and hybridization of the labeled probes were performed exactly according to the manufacturer's specifications. Signal was generated from the labeled probes by the addition of the detection reagent provided with the labeling kit. Membranes were exposed to Kodak XAR film for times varying from 30 s to 5 min, and the resultant luminograms were examined for bands corresponding to the positive control generated as described above.
RESULTS
Results from these experiments are summarized in Table 3 . The agarose gel from a typical PCR analysis of maternal and fetal blood samples is shown in Figure 1 . TNF-a mRNA was assayed in 16 maternal-fetal pairs. TNF-a mRNA was detected in all 18 fetal blood samples and in 15 of the 16 maternal samples. Although ethidium bromide-stained bands for fetal TNF-a were generally more prominent than bands from maternal samples, this was probably due to the more efficient 
5' ATC TGG CAC CAC ACC T C TAC AAT GAG CTG CG '3' Downstream (3') 5 ' C G T C A T A C T C C T G C T T G C T G A T C C A C A T C T G C 3 ' IL-Ip
Upstredm ( 5 ' ) 5' ATG GCA GAA GTA CCT AAG CTC GC 3' Downstream (3') 5' A CAC AAA TTG CAT GGT GAA GTC ACT T '3' TNFa Upstr~dn~ (5') GAG TGA CAA GCC TGT AGC CCA TGT TGT AGC A '3' Down\tlcarn (3') GCA ATG ATC CCA AAG TAG ACC TGC CCA GAC T 3' RNA isolation from fetal blood (which contains more nucleated cells in a given volume than maternal blood), inasmuch as P-actin bands tendcd to be brighter in these same samples (Fig.  1A) . The p-actin band in the mother with undetectable TNF-a mRNA was strongly positive, confirming that the RNA isolation, rcverse transcription, and PCR were as efficient as in the other maternal samples. PCR analysis for IL-lP, which was examined in 13 pregnancies, showed a different pattern (Fig. 2) . In three pregnancics (including one of the twin pregnancies), IL-1P was clearly negative. One pregnancy showcd discordance in IL-1P expression between mother and fetus, with the fetus showing a faint IL-1P band and the mother negative. In two other maternalfctal pairs, faint bands for IL-1P were produced by PCR. In seven prcgnancies, IL-1 P was clearly positive.
Expression of IL-1P may have been related to fetal exposure to viral infection, inasmuch as mRNA for this cytokine was clearly positive in the 22-wk fetus (and mother) with maternal varicella infection (patient 12), whereas weak bands were seen in both of the infants exposed to primary maternal cytomegalovirus infection. Because no attempt was made to make the PCR assays quantitative or even semiquantitative, no conclusions can be drawn regarding the level of TNF-a or IL-lP mRNA expression and specific clinical situations (e.g. intrauterine growth retardation).
DISCUSSION
The discovery that TNF-a, IL-1P, and IL-6 are expressed at the maternal-fetal interface has generated considerable interest in their role in pregnancy and the initiation of labor. Wegmann et ul. (5) have suggested that normal pregnancy requires a bidirectional, intercommunicating cytokine network that includes the maternal immune system and fetally derived placental tissues, especially placental trophoblasts (4) . Whether the fetus plays any role in this network is unknown. The finding of TNF-cr in fetal plasma as described by Abbas et al. (6) was supportive of a role for the fetus in this process. Howcver, monocytes obtained from both term and preterm infants postnatally have been shown to have little constitutive expression of either IL-1P or TNF-a, although such cells will respond to bacterial lipopolysaccharide to produce IL-1P and, to a lesser extent, TNF-a (9).
We have presented strong evidence for fetal cytokine mRNA expression In utero as early as 21 wk of gestation. The specific cytokines detected, TNF-a and IL-lP, are most commonly expressed in cells of the monocyte/macrophage lineage and suggest that this portion of the immune system is already well dcveloped by the second trimester. Why these cells transcribe low levels of TNF-a and IL-1P mRNA during fetal life is unclear. Although it is possible that low levels of mRNA for these cytokines may be detected in resting monocytes in normal infants or children (a question that we are currently addressing), it is also possible that expression of these cytokines reflects fetal participation in the so-called cytokine network of pregnancy. Alternatively, it could reflect the fact that the monocyte-macrophage system in the fetus is in an activated state due to rapid growth and differentiation. A similar hypothesis has been suggested for fetal T cells, a high percentage of which express the activation marker CD38 (7).
We have considered the possibility that the TNF-a and IL-1P mRNA amplified from cordocentesis specimens may have come from a few contaminating amniotic fluid cells. However, levels of fetal mRNA were, if anything, higher than the amount of mRNA from maternal blood. It therefore seems very unlikely that the cytokine mRNA amplified from the fetal samples came from anywhere but fetal blood.
We believe that PCR technology will be an important tool in the understanding of the immunobiology of the fetus and pregnancy, particularly in investigating the role of cytokines. Because most cytokines are secreted and act locally, and because expression of many cytokines is accompanied by expression of soluble receptors and inhibitors, there arc serious pitfalls in the measurement of these proteins in plasma by either bioassay or immunologic methods. The use of rtPCR, however, provides a sensitive, specific, and even quantitative method (10) for examining cytokine expression in vivo or in vitro. These techniques, coupled with our increasing ability to sample fetal tissue in vivo, provide the opportunity for significant advances in our understanding of fetal immunobiology in the near future.
